



PATENT APPLICATION  
File No: 00-79D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson  
Serial No. : 10/606,055  
Group Art Unit : 1649  
Examiner : Borgeest, C.  
Filed : June 25, 2003  
For : METHOD OF TREATING FIBROPROLIFERATIVE  
DISORDERS  
Date Submitted : October 28, 2005

**AMENDMENT FEE TRANSMITTAL**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

**CLAIMS AS AMENDED**

<u>Claim Type</u>	Total Claims <u>After Amendment</u>	Highest No. Covered by Previous Payments	Extra	Extra Rate	Fees
<u>Paid</u>					
Total	8	-20	0 x	<input checked="" type="checkbox"/> \$25 <input type="checkbox"/> \$50	\$0
Independent	1	-3	0 x	<input checked="" type="checkbox"/> \$100 <input type="checkbox"/> \$200	\$0
					Total: \$0

Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker  
Registration No. 31,648




JPN

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Oct. 28, 2005

Date



Gary E. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Charles E. Hart et al.  
Serial No. : 10/606,055  
Filed : June 25, 2003  
For : METHOD OF TREATING FIBROPROLIFERATIVE  
DISORDERS  
Examiner : Borgeest, C.  
Art Unit : 1649  
Docket No. : 00-79D1  
Date : October 28, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Amendment and Response to Restriction Requirement

Sir:

In response to the Office Action dated September 30, 2005, please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.